bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
1.500
+0.050 (3.45%)
Nov 28, 2025, 4:00 PM EST - Market closed
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.45M in the quarter ending September 30, 2025, a decrease of -38.48%. This brings the company's revenue in the last twelve months to $6.78M, down -27.66% year-over-year. In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth.
Revenue (ttm)
$6.78M
Revenue Growth
-27.66%
P/S Ratio
0.16
Revenue / Employee
$118,890
Employees
57
Market Cap
6.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BIAF News
- 14 days ago - bioAffinity Technologies Reports Third Quarter 2025 Financial Results - Business Wire
- 23 days ago - bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume - Business Wire
- 4 weeks ago - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases - Business Wire
- 5 weeks ago - bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 - Business Wire
- 6 weeks ago - bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer - Business Wire
- 6 weeks ago - bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Business Wire
- 7 weeks ago - WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 7 weeks ago - bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Business Wire